Post-transcriptional Control of Gene Expression: Mechanisms of mRNA Decay

描述（由申请人提供）：我们请求部分支持FASEB会议“基因表达的转录后调节：mRNA衰变机制”，将于2006年6月24日至29日在斯诺马斯村，CO举行。 mRNA的周转是基因表达的一个关键，但经常未被认识到的调节因子。 mRNA的稳定性决定了其最终的稳态水平。 程序性不稳定性是抑制基因表达的重要机制，mRNA质量的监测确保只有“合适”的转录物离开细胞核并被翻译，而RNA干扰依赖于选择性mRNA周转来产生生物学后果，而新型药物则靶向mRNA衰变途径。 由于这些原因，mRNA周转率正引起生命科学所有领域的高度关注。 拟议的FASEB会议是独一无二的，专注于mRNA衰变，从而探索在不同的生物环境中的机制，无论是在细胞和分子水平上，支持这一普遍的过程。 拟议中的会议是特别值得注意的吸引研究人员谁研究原核和真核生物，并在集中的机制，其中RNA相互作用的衰变装置，翻译装置，以及调节衰变的因素。 会议的会议将讨论特定于mRNA 5'或3'末端及其亚细胞定位的衰变事件; RNA结合蛋白，小RNA和其他衰变因子的结构/功能关系; mRNA衰变与翻译和转录过程的相互作用; RNA质量控制和相关监管网络;以及mRNA衰变的临床和药学相关性。 预计会议上的演讲将包括几个关键结构和机制的首次公开披露，并为生长，发育和疾病的调节提供新的见解。 简而言之，会议将概述一个令人兴奋的领域的最新进展，并将推动其发展的下一阶段。

DESCRIPTION (provided by applicant): We are requesting partial support for a FASEB Conference on "Post-Transcriptional Regulation of Gene Expression: Mechanisms of mRNA Decay", to be held in Snowmass Village, CO on June 24-29, 2006. Turnover of mRNA is a key, but frequently unrecognized, regulator of gene expression. The stability of an mRNA dictates its ultimate steady-state level. Programmed instability is an important mechanism of repressing gene expression, and the surveillance of mRNA quality ensures that only "fit" transcripts exit the nucleus and are translated, while RNA interference relies on selective mRNA turnover for its biological consequences, whereas novel pharmaceuticals are targeting mRNA decay pathways. For these reasons, mRNA turnover is attracting heightened interest from all areas of the life sciences. The proposed FASEB Conference is unique in concentrating on mRNA decay, thereby exploring in diverse biological settings the mechanisms, both at the cellular and molecular levels that underpin this universal process. The proposed meeting is particularly noteworthy in attracting investigators who study both prokaryotic and eukaryotic organisms, and in focusing on mechanisms by which RNAs interact with the decay apparatus, the translation apparatus, and the factors which modulate decay. The meeting's sessions will address decay events specific for mRNA 5' or 3' termini and their subcellular localization; structure/function relationships in RNA binding proteins, small RNAs, and other decay factors; the interplay of mRNA decay with the processes of translation and transcription; RNA quality control and related regulatory networks; and the clinical and pharmaceutical relevance of mRNA decay. It is anticipated that the presentations at the meeting will include the first public disclosures of several key structures and mechanisms, as well as provide novel insights for the regulation of growth, development, and disease. In short, the conference will provide an overview of the latest progress in an exciting field and will propel the next stage of its development.